Literature DB >> 8359090

Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy.

M Yoshiba1, K Sekiyama, S Iwabuchi, M Takatori, Y Tanaka, T Uchikoshi, H Okamoto, K Inoue, F Sugata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8359090     DOI： 10.1007/bf01303187

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

2.  Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy.

Authors:  M A Flowers; J Heathcote; I R Wanless; M Sherman; W J Reynolds; R G Cameron; G A Levy; R D Inman
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

3.  Hepatitis B virus DNA in fulminant hepatitis B.

Authors:  K M De Cock; S Govindarajan; B Valinluck; A G Redeker
Journal:  Ann Intern Med       Date:  1986-10       Impact factor: 25.391

4.  Multiplication of hepatitis B virus in fulminant hepatitis B.

Authors:  C Brechot; J Bernuau; V Thiers; F Dubois; A Goudeau; B Rueff; P Tiollais; J P Benhamou
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

5.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

6.  Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers.

Authors:  G L Bird; H Smith; B Portmann; G J Alexander; R Williams
Journal:  Q J Med       Date:  1989-10

7.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.

Authors:  H Okamoto; S Yotsumoto; Y Akahane; T Yamanaka; Y Miyazaki; Y Sugai; F Tsuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.

Authors:  H Okamoto; S Okada; Y Sugiyama; T Tanaka; Y Sugai; Y Akahane; A Machida; S Mishiro; H Yoshizawa; Y Miyakawa
Journal:  Jpn J Exp Med       Date:  1990-08

9.  Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes.

Authors:  M Yoshiba; K Sekiyama; Y Iwamura; F Sugata
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199
  9 in total
  5 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

Authors:  T Sato; J Kato; J Kawanishi; K Kogawa; M Ohya; S Sakamaki; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

3.  Molecular epidemiology of an outbreak of fulminant hepatitis B.

Authors:  N Petrosillo; G Ippolito; L Solforosi; P E Varaldo; M Clementi; A Manzin
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.

Authors:  F ter Borg; S Smorenburg; R A de Man; R C Rietbroek; R A Chamuleau; E A Jones
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

5.  Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

Authors:  Takeaki Takenaka; Kuniaki Itoh; Takayo Suzuki; Atae Utsunomiya; Shin Matsuda; Takaaki Chou; Toshiaki Sai; Masayuki Sano; Susumu Konda; Tatsuji Ohno; Chikara Mikuni; Kijoh Deura; Takashi Yamada; Fumi Mizorogi; Haruhisa Nagoshi; Masao Tomonaga; Tomomitsu Hotta; Kohichi Kawano; Keitaro Tsushita; Masami Hirano; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.